汇聚创新资源 "首款""首个"成果集中亮相 漫步博览会开幕式现场，"含金量"满满。 汇聚业界顶尖专家。来自中国科学院、中国工程院、美国心脏学会的院士代表，以及上百名顶尖医 学专家齐聚一堂，带来了前沿的学术思考。 全球前沿成果首秀。辉瑞、罗氏诊断、美敦力、强生等近80家行业巨头参展，并亮出"看家本 领"——小细胞肺癌创新药物、全球首款智能人工耳蜗系统……上百款国际创新药械、特医食品及生物 医学新技术集中发布，涵盖肿瘤、AI诊疗、细胞治疗等多个前沿领域。 首届全球创新药械博览会发布上百款创新药械及技术 乐城打造医疗创新转化"强磁场" 海南日报全媒体见习记者 王子豪 11月21日至22日，博鳌乐城国际医疗旅游先行区(以下简称乐城先行区)，让人再次感受到全球医疗 创新的脉动。海南博鳌乐城首届全球创新药械博览会(以下简称博览会)在这里拉开帷幕，为期两天的盛 会，以"智汇全球创新技术，共筑人类健康未来"为主题，吸引了上百位国内外权威专家、近80家全球药 械领军企业现场参展。 这不仅仅是一场展会。在乐城，通过搭建跨越国界的合作桥梁，一条贯通"政企产学研"的医疗创新 转化新路径正在清晰浮现，全球前沿医疗成果正从"纸面上的创新 ...

Core Insights - SMIC made significant strides in the semiconductor industry by reducing prices of 28nm technology by 40%, leading to a rapid increase in market share [1] - Japan dominates the photoresist market, holding approximately 90% of the global share, which poses a risk for countries reliant on imports [1][5] - China has made advancements in developing its own photoresist, specifically the T150A, which has passed mass production verification and is expected to enhance domestic semiconductor capabilities [7][8] Industry Overview - The photoresist market is crucial for semiconductor manufacturing, with Japan maintaining a stronghold on technology and supply [5][10] - Other countries, including the US, Germany, and South Korea, are also involved in the photoresist sector, but Japan's technological advancements have created a significant gap [3][5] - The global market for photoresist is heavily influenced by Japan's supply chain decisions, as evidenced by the four-year suspension of supplies to South Korea, which highlighted the risks of dependency [5][16] Technological Developments - China's T150A photoresist has achieved a resolution of 120nm, surpassing similar foreign products, marking a pivotal moment in reducing reliance on Japanese imports [8][14] - The development of domestic photoresist technology is seen as a critical step towards self-sufficiency in the semiconductor industry, allowing China to mitigate risks associated with potential supply disruptions from Japan [8][14] Competitive Landscape - South Korea has also recognized the need to develop its own photoresist technology, leading to increased domestic production and reduced reliance on Japanese imports [16] - Japan's previous confidence in its market dominance has been challenged by the advancements made by other countries, indicating a shift in the competitive dynamics of the photoresist industry [16]

Core Viewpoints - The article summarizes the insights from fund managers based on their Q1 2025 reports, focusing on their investment strategies and market outlooks [1]. Group 1: Fund Manager Perspectives - Fund managers typically cover two main areas in their reports: a review of past investments and future market outlooks, with the latter being more significant [3]. - Different fund managers exhibit varying levels of detail in their reports, influenced by their investment styles, such as value or growth [3]. - The deep value style emphasizes low valuations and high dividend yields, primarily investing in sectors like finance, real estate, and energy [4][5]. - Growth value style focuses on companies with strong profitability and cash flow, often holding stocks for the long term [10]. Group 2: Deep Value Style Insights - Deep value style has shown strong performance from 2021 to 2024, while it underperformed in 2019-2020 [6]. - Fund managers express confidence in their holdings despite market uncertainties, citing factors like geopolitical changes and technological advancements as influential [7]. - The current market environment is characterized by structural changes, with some sectors facing prolonged competition, while others show clear competitive advantages [7]. Group 3: Growth Value Style Insights - Growth value managers highlight the resilience of high-frequency economic data and improved financing conditions, suggesting a positive outlook for the second quarter [12]. - They emphasize the importance of focusing on domestic economic transformation and internal demand rather than external pressures [12][13]. - Fund managers are adjusting their portfolios to capitalize on sectors like AI and healthcare, anticipating a shift in consumer behavior and market dynamics [15][16]. Group 4: Balanced Style Insights - The balanced style seeks to combine growth potential with valuation, often looking for stocks that offer good value relative to their growth prospects [26]. - Fund managers maintain a diversified approach, focusing on sectors with favorable valuations and growth potential, such as healthcare and technology [29][30]. - They express optimism about domestic consumption policies and liquidity, which may support market performance despite external uncertainties [30]. Group 5: Growth Style Insights - The growth style prioritizes companies with high revenue and profit growth, often accepting higher valuations for strong growth potential [39][40]. - Fund managers are actively seeking opportunities in emerging industries, such as renewable energy and technology, which are expected to drive future growth [41].

Core Insights - The Boao Lecheng International Medical Tourism Pilot Zone has seen a significant increase in the usage of special medical devices and drugs, with a reported 44.14% year-on-year growth in usage instances in the first quarter of 2025, reaching 16,000 instances [2] - The collaboration among various departments has led to innovative regulatory measures that have streamlined the approval process, resulting in a substantial increase in the number of approved medical devices and drugs [2][3] Summary by Sections Usage Growth - In the first quarter of 2025, the usage of special medical devices and drugs in Lecheng reached 16,000 instances, marking a 44.14% increase compared to the previous year [2] - The total usage for 2024 is projected to exceed 51,000 instances, reflecting a 79.33% year-on-year growth [2] - The value of special medical devices entering the bonded warehouse reached 602 million yuan, an 18% increase year-on-year [2] Regulatory Innovations - Since 2021, the provincial drug regulatory authority, health commission, and customs have implemented measures to support high-quality development in the Lecheng pilot zone, including adjustments to the approval process [2] - The approval process has shifted from a "one person, one product, one batch" model to a "one product, one hospital, one batch" model, significantly increasing the number of approvals [2] Patient and Institutional Engagement - The implementation of a drug and device exit registration measure has led to a noticeable increase in patient willingness to use these products, benefiting over 17,000 patients [3] - The regulatory authority is focusing on patient needs and is actively seeking products that can create usage scale and extend the industry chain [3] - A shared service platform for special medical devices and drugs is being developed to enhance communication and service delivery, transforming the approval process from passive to proactive [3]